Abstract
MicroRNA (miR)-125b has been identified as deregulated in a number of types of cancer. Previous studies have detected the expression of miR-125b in clear cell renal cell carcinoma (ccRCC) tissues by in situ hybridization and revealed that miR-125b was upregulated in ccRCC tissues, and was associated with recurrence and survival of patients with ccRCC. However, the function of miR-125b in RCC remains unclear. Thus, the expression of miR-125b was detected with quantitative polymerase chain reaction (qPCR) in 24 paired RCC and adjacent normal tissues. The result of qPCR showed that miR-125b was upregulated in RCC tissues. Furthermore, the function of miR-125b in RCC (786-O and ACHN) cells was detected by transfecting miR-125 mimic or inhibitor to upregulate or downregulate miR-125b expression. Cell proliferation assays (MTT and Cell Counting Kit-8), cell mobility assays (cell scratch and Transwell assay) and a cell apoptotic assay (flow cytometry assay) were performed to assess the function of miR-125b on RCC cells. Results from the assays demonstrated that overexpression of miR-125b could promote cell migration and invasion, and reduce the cell apoptotic rate. It was also revealed that downregulation of miR-125b could reduce cell migration and invasion, and induce cell apoptosis. However, the results of the cell proliferation assay revealed that miR-125b had no significant effect on cell proliferation. Not only could miR-125b predict recurrence and survival of ccRCC; the present study revealed that miR-125b could regulate RCC cell migration, invasion and apoptosis. Additional studies are required to determine the mechanism of miR-125b in RCC cells and define the target genes of miR-125b in RCC.
Highlights
Renal cell carcinoma (RCC) is the most common type of renal cancer, accounting for ~3% of malignancies in adults [1]
Deregulation of miRNAs has been detected in numerous types of cancer, including RCC and gastric cancer [11,16], and has been confirmed to be capable of promoting cancer initiation and progression [11], a number of which function as oncogenes or tumor suppressors, depending on the differences of the targeted gene
The expression of miR‐125b has been revealed to be deregulated in a number of types of cancer, including gastric cancer [16], non‐small‐cell lung cancer (NSCLC) [19] and osteosarcoma [12]
Summary
Renal cell carcinoma (RCC) is the most common type of renal cancer, accounting for ~3% of malignancies in adults [1]. The prognosis of advanced cancer is reported to be poor, with a 5‐year survival rate of 5‐10% [2,3]. RCC has no characteristic symptom, so ~30% of patients are presented with metastatic disease at the time of diagnosis. Radical nephrectomy is the primary treatment choice for patients with RCC, due to the resistance of radiotherapy and chemotherapy [4,5]. 20‐40% of patients developed recurrence following the curative nephrectomy [6]. It is important to find a biomarker of RCC for early diagnosis and targeted therapy based on the mechanisms of RCC tumorigenesis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
